Viability and Cardiac Resynchronization Therapy

Summary

30% of heart failure patients that receive a device for cardiac resynchronization therapy fail to show clinical improvement. The reason for lack of response is still unclear but factors such as scar tissue in the heart musculature, inadequate lead placement, device-settings and the degree of dyssynchrony before implant seems to be important. In this study, these factors are further investigated.

Conditions

• Heart Failure
• Ischemic Cardiomyopathy

Interventions

DEVICE

AV-optimization followed by AV- and VV-optimization

Patients are AV-optimized the first 4 months,then AV- and VV-optimized the next 4 months.

DEVICE

AV- and VV-optimization followed by AV-optimization only.

Patients are AV- and VV-optimized the first 4 months,then AV-optimized the next 4 months.

Sponsors & Collaborators

• Lund University Hospital

  collaborator OTHER

• Rigshospitalet, Denmark

  collaborator OTHER

• University Hospital, Gentofte, Copenhagen

  lead OTHER

Principal Investigators

• Niels Risum, M.D. · University Hospital Gentofte, Department of cardiology

• Thomas Fritz Hansen, M.D. · University Hospital Gentofte, department of cardiology

• Peter Søgaard, M.D., DMSc. · Gentofte University Hospital, department of cardiology

• Rasmus Borgquist, MD, PhD · University Hospital Lund

• Niels E Bruun, MD, DMSc · Gentofte University Hospital, department of cardiology

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

CROSSOVER

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2009-08-31

Primary Completion

2012-12-31

Completion

2013-06-30

Countries

• Denmark
• Sweden

Study Locations